Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Fabre-Kramer Pharmaceuticals Inc.
DescriptionBinds to dopamine D2 receptor, dopamine D3 receptor, serotonin (5-HT2C) receptor, serotonin (5-HT2A) receptor and histamine H1 receptor
Molecular Target Dopamine D2 receptor ; Serotonin (5-HT2) receptor
Mechanism of ActionSerotonin (5-HT2A) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today